메뉴 건너뛰기




Volumn 14, Issue 3, 1998, Pages 241-250

The need for pharmacoeconomic evaluations in the NHS

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ALBENDAZOLE; ALLOPURINOL; AMANTADINE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA1A INTERFERON; CALCITONIN; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CHLOROQUINE; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DONEPEZIL; FLUOXETINE; GABAPENTIN; INTERFERON BETA SERINE; LAMOTRIGINE; PACLITAXEL; PAROXETINE; PHENYTOIN; PRAZOSIN; RILUZOLE; THALIDOMIDE; TIAGABINE; UNINDEXED DRUG; VIGABATRIN; ZIDOVUDINE; ZONISAMIDE;

EID: 0031693280     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199814030-00001     Document Type: Review
Times cited : (8)

References (47)
  • 2
    • 84990525766 scopus 로고
    • Proposed UK NHS prescribing list
    • Bonn D. Proposed UK NHS prescribing list [letter]. Lancet 1994; 344: 1495
    • (1994) Lancet , vol.344 , pp. 1495
    • Bonn, D.1
  • 3
    • 0028017281 scopus 로고
    • Controlling the NHS drugs budget
    • Murfin D. Controlling the NHS drugs budget [letter]. BMJ 1994; 309: 957
    • (1994) BMJ , vol.309 , pp. 957
    • Murfin, D.1
  • 4
    • 0027096561 scopus 로고
    • The economic implications of therapeutic conservatism
    • Griffin TD. The economic implications of therapeutic conservatism. Int Pharm J 1992; 6: 269-71
    • (1992) Int Pharm J , vol.6 , pp. 269-271
    • Griffin, T.D.1
  • 5
    • 0029042039 scopus 로고
    • A UK national prescribing list?
    • Walley T. A UK national prescribing list? Pharmacoeconomics 1995; 7 (6): 471-4
    • (1995) Pharmacoeconomics , vol.7 , Issue.6 , pp. 471-474
    • Walley, T.1
  • 6
    • 0027267367 scopus 로고
    • The economic implications of therapeutic conservatism
    • Griffin JP, Griffin TD. The economic implications of therapeutic conservatism. J R Coll Physicians Lond 1993; 27: 121-6
    • (1993) J R Coll Physicians Lond , vol.27 , pp. 121-126
    • Griffin, J.P.1    Griffin, T.D.2
  • 7
    • 0028912005 scopus 로고
    • Therapeutic conservatism: More costly in the long term?
    • Griffin JP. Therapeutic conservatism: more costly in the long term? Pharmacoeconomics 1995; 7: 378-87
    • (1995) Pharmacoeconomics , vol.7 , pp. 378-387
    • Griffin, J.P.1
  • 10
    • 7344229573 scopus 로고    scopus 로고
    • Rationing and priorities in the NHS
    • January 5; Sect. A: (col. 3)
    • Neuberger J. Rationing and priorities in the NHS. The Times 1998 January 5; Sect. A: 21 (col. 3)
    • (1998) The Times , pp. 21
    • Neuberger, J.1
  • 11
    • 0040821125 scopus 로고
    • Challenges for the National Health Service
    • Teeling-Smith G, editor. London: Office of Health Economics
    • Powell JE. Challenges for the National Health Service. In: Teeling-Smith G, editor. Innovative competition in medicine. London: Office of Health Economics, 1992: 97-107
    • (1992) Innovative Competition in Medicine , pp. 97-107
    • Powell, J.E.1
  • 12
    • 7344255964 scopus 로고
    • Health care dilemmas
    • Teeling-Smith G, editor. London: Office of Health Economics
    • Jenkin P. Health care dilemmas. In: Teeling-Smith G, editor. Innovative competition in medicine. London: Office of Health Economics, 1992: 108
    • (1992) Innovative Competition in Medicine , pp. 108
    • Jenkin, P.1
  • 13
    • 7344237592 scopus 로고    scopus 로고
    • A new rationing debate begins in the UK
    • Dean M. A new rationing debate begins in the UK [abstract]. Lancet 1997; 35: 1305
    • (1997) Lancet , vol.35 , pp. 1305
    • Dean, M.1
  • 14
    • 0018601817 scopus 로고
    • Constraints of drug regulation on the development of new drugs
    • Gross F. Constraints of drug regulation on the development of new drugs. Arch Toxicol 1979; 43: 9-17
    • (1979) Arch Toxicol , vol.43 , pp. 9-17
    • Gross, F.1
  • 15
    • 0019441928 scopus 로고
    • A survey of products licensed in the United Kingdom from 1971-1981
    • Griffin JP, Diggle GE. A survey of products licensed in the United Kingdom from 1971-1981. Br J Clin Pharmacol 1981; 12: 453-63
    • (1981) Br J Clin Pharmacol , vol.12 , pp. 453-463
    • Griffin, J.P.1    Diggle, G.E.2
  • 16
    • 7344249196 scopus 로고    scopus 로고
    • The Schwartz view
    • Schwartz H. The Schwartz view. Scrip Mag 1997; Dec: 7-8
    • (1997) Scrip Mag , vol.DEC , pp. 7-8
    • Schwartz, H.1
  • 17
    • 7344261492 scopus 로고    scopus 로고
    • The Schwartz view
    • Schwartz H. The Schwartz view. Scrip Mag 1998; Mar: 13-5
    • (1998) Scrip Mag , vol.MAR , pp. 13-15
    • Schwartz, H.1
  • 18
    • 0031459202 scopus 로고    scopus 로고
    • Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system
    • Stahl MMS, Lindquist M, Petterson M, et al. Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system. Eur J Clin Pharmacol 1997; 53: 163-9
    • (1997) Eur J Clin Pharmacol , vol.53 , pp. 163-169
    • Stahl, M.M.S.1    Lindquist, M.2    Petterson, M.3
  • 19
    • 0029801305 scopus 로고    scopus 로고
    • Interferon beta in multiple sclerosis: Clinical cost effectiveness falls at fiist hurdle
    • Richards RG. Interferon beta in multiple sclerosis: clinical cost effectiveness falls at fiist hurdle [letter]. BMJ 1996; 313: 1159
    • (1996) BMJ , vol.313 , pp. 1159
    • Richards, R.G.1
  • 20
    • 0029841601 scopus 로고    scopus 로고
    • Newly licensed drugs should be on probation until their value is demonstrated
    • Ferner RE. Newly licensed drugs should be on probation until their value is demonstrated. BMJ 1996; 313: 1157-8
    • (1996) BMJ , vol.313 , pp. 1157-1158
    • Ferner, R.E.1
  • 21
    • 0031965368 scopus 로고    scopus 로고
    • Interferon beta-1a for multiple sclerosis
    • Interferon beta-1a for multiple sclerosis. Drug Ther Bull 1998; 36: 7-8
    • (1998) Drug Ther Bull , vol.36 , pp. 7-8
  • 22
    • 0032499366 scopus 로고    scopus 로고
    • Interferon beta produces only small benefits in multiple sclerosis
    • McKee L. Interferon beta produces only small benefits in multiple sclerosis [abstract]. BMJ 1998; 316: 1410
    • (1998) BMJ , vol.316 , pp. 1410
    • McKee, L.1
  • 23
    • 0030714579 scopus 로고    scopus 로고
    • Too soon to market: Doctors and patients need more information before drugs enter routine use
    • Dent THS, Hauke S. Too soon to market: doctors and patients need more information before drugs enter routine use. BMJ 1997; 315: 1248-9
    • (1997) BMJ , vol.315 , pp. 1248-1249
    • Dent, T.H.S.1    Hauke, S.2
  • 24
    • 85007670693 scopus 로고    scopus 로고
    • Too soon to market: Statistical aspects of research done outside the pharmaceutical industry could be improved
    • Senn S. Too soon to market: statistical aspects of research done outside the pharmaceutical industry could be improved [letter]. BMJ 1998; 316: 228
    • (1998) BMJ , vol.316 , pp. 228
    • Senn, S.1
  • 25
    • 85007670693 scopus 로고    scopus 로고
    • Too soon to market: Data available before products launched are poor
    • Clark W, Fisher M, Misson J. Too soon to market: data available before products launched are poor. BMJ 1998; 316: 228-9
    • (1998) BMJ , vol.316 , pp. 228-229
    • Clark, W.1    Fisher, M.2    Misson, J.3
  • 26
    • 0032539309 scopus 로고    scopus 로고
    • Too soon to market: Problems apply to introduction of new prosthetic implants as well as drugs
    • Sochart DH. Too soon to market: problems apply to introduction of new prosthetic implants as well as drugs [letter]. BMJ 1998; 316: 229
    • (1998) BMJ , vol.316 , pp. 229
    • Sochart, D.H.1
  • 27
    • 0032539274 scopus 로고    scopus 로고
    • Too soon to market: Problem is acute in dermatology
    • Williams HC. Too soon to market: problem is acute in dermatology [letter]. BMJ 1998; 316: 229
    • (1998) BMJ , vol.316 , pp. 229
    • Williams, H.C.1
  • 28
    • 0032539304 scopus 로고    scopus 로고
    • Too soon to market: Problem does not just occur with British markets
    • Wolff F. Too soon to market: problem does not just occur with British markets [letter]. BMJ 1998; 316: 229
    • (1998) BMJ , vol.316 , pp. 229
    • Wolff, F.1
  • 29
    • 33646836642 scopus 로고    scopus 로고
    • Drug trials in epilepsy: New drugs have been poorly assessed
    • Mignot G. Drug trials in epilepsy: new drugs have been poorly assessed [letter]. BMJ 1996; 313: 1158
    • (1996) BMJ , vol.313 , pp. 1158
    • Mignot, G.1
  • 30
    • 0030577195 scopus 로고    scopus 로고
    • Long term use of lamotrigine and vigabatrin in severe refractory epilepsy: Audit of outcome
    • Walker MC, Li LM, Sander WAS. Long term use of lamotrigine and vigabatrin in severe refractory epilepsy: audit of outcome. BMJ 1996; 313: 1184-5
    • (1996) BMJ , vol.313 , pp. 1184-1185
    • Walker, M.C.1    Li, L.M.2    Sander, W.A.S.3
  • 31
    • 0029822510 scopus 로고    scopus 로고
    • New antiepleptic drugs: A systematic review of their efficacy and tolerability
    • Marson AG, Kadir ZA, Chadwick DW. New antiepleptic drugs: a systematic review of their efficacy and tolerability. BMJ 1996; 313: 1169-74
    • (1996) BMJ , vol.313 , pp. 1169-1174
    • Marson, A.G.1    Kadir, Z.A.2    Chadwick, D.W.3
  • 32
    • 0030707474 scopus 로고    scopus 로고
    • Economic evaluation of pharmaceuticals: What are reasonable standards for clinical evidence - The Australian experience
    • Hill S, Henry D, Pekarsky B, et al. Economic evaluation of pharmaceuticals: what are reasonable standards for clinical evidence - the Australian experience. Br J Clin Pharmacol 1997; 44: 421-5
    • (1997) Br J Clin Pharmacol , vol.44 , pp. 421-425
    • Hill, S.1    Henry, D.2    Pekarsky, B.3
  • 33
    • 7344231286 scopus 로고    scopus 로고
    • A clinical benefit must not be confused with cost benefit
    • Rawlins M, Breckenridge A. A clinical benefit must not be confused with cost benefit [letter]. BMJ 1998; 316: 400
    • (1998) BMJ , vol.316 , pp. 400
    • Rawlins, M.1    Breckenridge, A.2
  • 35
    • 0030747752 scopus 로고
    • Regulating the pharmaceutical industry
    • Maynard A, Bloor K. Regulating the pharmaceutical industry. BMJ 1947; 315: 200-1
    • (1947) BMJ , vol.315 , pp. 200-201
    • Maynard, A.1    Bloor, K.2
  • 37
    • 0032539373 scopus 로고    scopus 로고
    • Regulating the pharmaceutical industry: General public does not support value system inherent in cost-effectiveness analyses
    • Furniss J, Zammit-Lucia J, Johnson N. Regulating the pharmaceutical industry: general public does not support value system inherent in cost-effectiveness analyses [letter]. BMJ 1998; 316: 226
    • (1998) BMJ , vol.316 , pp. 226
    • Furniss, J.1    Zammit-Lucia, J.2    Johnson, N.3
  • 38
    • 85044700943 scopus 로고    scopus 로고
    • Regulating the pharmaceutical industry: Authors seem to have misunderstood the pharmaceutical price regulation scheme
    • Read P. Regulating the pharmaceutical industry: authors seem to have misunderstood the pharmaceutical price regulation scheme [letter]. BMJ 1998; 316: 226
    • (1998) BMJ , vol.316 , pp. 226
    • Read, P.1
  • 39
    • 0032539319 scopus 로고    scopus 로고
    • Regulating the pharmaceutical industry: Having rationing rules for new pharmaceuticals but not other treatments is senseless
    • Towse A. Regulating the pharmaceutical industry: having rationing rules for new pharmaceuticals but not other treatments is senseless [letter]. BMJ 1998; 316: 227
    • (1998) BMJ , vol.316 , pp. 227
    • Towse, A.1
  • 40
    • 0032539303 scopus 로고    scopus 로고
    • Regulating the pharmaceutical industry: Regulation may no longer be necessary
    • Rowlatt P. Regulating the pharmaceutical industry: regulation may no longer be necessary [letter]. BMJ 1998; 316: 227
    • (1998) BMJ , vol.316 , pp. 227
    • Rowlatt, P.1
  • 41
    • 0032539282 scopus 로고    scopus 로고
    • Regulating the pharmaceutical industry: Further controls would discourage companies investing in research
    • Lance S. Regulating the pharmaceutical industry: further controls would discourage companies investing in research [letter]. BMJ 1998; 316: 227-8
    • (1998) BMJ , vol.316 , pp. 227-228
    • Lance, S.1
  • 42
    • 0028889889 scopus 로고
    • Support for trials of promising medications through the Pharmaceutical Benefits Scheme
    • Glasziou PP. Support for trials of promising medications through the Pharmaceutical Benefits Scheme. Med J Aust 1995; 162: 33-6
    • (1995) Med J Aust , vol.162 , pp. 33-36
    • Glasziou, P.P.1
  • 43
    • 0032539323 scopus 로고    scopus 로고
    • Regulating the pharmaceutical industry: Australian scheme has disadvantages
    • Clear PR, Grobler M. Regulating the pharmaceutical industry: Australian scheme has disadvantages [letter]. BMJ 1998; 316: 227
    • (1998) BMJ , vol.316 , pp. 227
    • Clear, P.R.1    Grobler, M.2
  • 44
    • 7344258516 scopus 로고    scopus 로고
    • The pros and cons of the PPRS
    • Griffin JP. The pros and cons of the PPRS. Scrip Mag 1997; Oct: 11-3
    • (1997) Scrip Mag , vol.OCT , pp. 11-13
    • Griffin, J.P.1
  • 45
    • 84887256630 scopus 로고
    • Risk assessment: A changing perspective
    • Mann RD, editor. Carnforth (Lancashire): Parthenon Publishing
    • Griffin JP. Risk assessment: a changing perspective. In: Mann RD, editor. Risk and consent to risk in medicine. Carnforth (Lancashire): Parthenon Publishing, 1989: 133-53
    • (1989) Risk and Consent to Risk in Medicine , pp. 133-153
    • Griffin, J.P.1
  • 46
    • 0003665913 scopus 로고    scopus 로고
    • London: Publ Stationary Office Ltd.
    • Department of Health. The new NHS: modern dependable CM3807. London: Publ Stationary Office Ltd., 1997
    • (1997) The New NHS: Modern Dependable CM3807
  • 47
    • 7344221693 scopus 로고    scopus 로고
    • Reimbursement for Viagra unlikely in Germany
    • Reimbursement for Viagra unlikely in Germany. Eur Drug Device Rep 1998; 8 (13): 5
    • (1998) Eur Drug Device Rep , vol.8 , Issue.13 , pp. 5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.